GLP-1 agonists are a whole class of drugs with various generic and brand names semaglutide (Ozempic/Wegovy/Rybelsus), dulaglutide (Trulicity), exenatide (Byetta), liraglutide (Saxenda/Victoza) and tirzepatide (Mounjaro/Zepbound) to name a few
These results represented a breakthrough in obesity pharmacotherapy and led to FDA approval of Zepbound
For many, weight gain is not a failure of willpower, but a complex medical condition influenced by genetics, hormones, and metabolic signaling
On December 19, 2025, Eli Lilly announced that retatrutide produced 28.7% body weight loss in the Phase 3 TRIUMPH-4 trial
This process is called glycogenolysis and provides a short-term source of glucose when blood glucose levels are low, such as during an overnight fast or a bout of intense exercise (Matsui 2012
The study's results suggested that the various IGF-1 analogs, including Receptor Grade IGF-1 LR3, appear to potentially reverse adverse myostatin and prevent apoptosis